Recent news on Pentostatin

SuperGen Reports 2007 First Quarter Financial Results  -  May 2, 2007
PR Newswire (press release),...of the Company's North American rights for Nipent(R) (pentostatin for injection) and Surface Safe(R) to Mayne Pharma that was effective in August 2006.

Nipent(R) Acquisition by Hospira is Complete  -  Apr 5, 2007
Drug Newswire (press release),...for Nipent(R) (pentostatin for injection) to Mayne Pharma, which was acquired in February 2007 by Hospira, for a total consideration of US$8 million.

Nipent(R) Acquisition by Hospira is Complete  -  Apr 3, 2007
Earthtimes.orgDUBLIN, Calif., April 3 -- SuperGen Inc. today announced that it closed on the sale of the remaining worldwide rights for Nipent(R) (pentostatin for

SuperGen Reports 2006 Fourth Quarter and Year-End Financial Results  -  Mar 28, 2007
Drug Newswire (press release),...a reduction in Nipent(R) (pentostatin for injection) and Surface Safe(R) net product revenue due to the sale of the US commercial business,

Increased Risk of Second Malignancies in Hairy Cell Leukemia  -  Feb 15, 2007
Cancer Consultants (press release),However, other treatments such as Nipent® (deoxycoformycin, pentostatin), interferon-alpha, splenectomy, and Rituxan® are also effective.

Mayo Clinic Cancer Center Collaborating To Find New Tools To Fight ...  -  Dec 14, 2006
Medical News Today (press release),..."We and our collaborators at Ohio State University, in particular Dr. Michael Grever, have done previous research on pentostatin that led us to believe

3-Drug Regimen Is New Tool in Leukemia Fight  -  Dec 11, 2006
Washington Post,..."We and our collaborators at Ohio State University... have done previous research on pentostatin that led us to believe there would be success with this

3-Drug Regimen Is New Tool in Leukemia Fight  -  Dec 11, 2006
Bru Direct,A combination of three chemotherapy drugs -- pentostatin, cyclophosphamide and rituximab -- produced significant clinical response in patients with

3-Drug Regimen Is New Tool in Leukemia Fight  -  Dec 11, 2006
Therapeutics Daily (subscription) (press release),11 (HealthDay News) -- A combination of three chemotherapy drugs -- pentostatin, cyclophosphamide and rituximab -- produced significant clinical response in

Mayne Acquires Remaining Rights to Hairy-Cell Leukemia Drug  -  Nov 27, 2006
Genetic Engineering News (press release),In August 2006, Mayne paid $34 million for the North American rights to Nipent® (pentostatin for injection). SuperGen will receive approximately $3.75

Mayne Pharma Acquires Remaining Nipent Rights  -  Nov 27, 2006
PharmaLive.com (press release),...that Mayne has agreed to acquire the remaining worldwide rights to Nipent(R) (pentostatin for injection) for a total consideration of US $8 million.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional